RxDoctor Payments Data

Daniel Muldoon, MD

Family Medicine · Fredericksburg, VANPI 1154384089

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 79 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$375
  • Novo Nordisk$242
  • Amgen$160
  • Astellas Pharma US Inc$124
  • Pfizer$83
  • Lilly USA, LLC$65
  • plus $616 from 19 others

What the payments were for

  • Food & beverage$1,64399%
  • Entertainment$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,666 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$91,091
Medicare patients
308
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin72$75,603
EliquisApixaban36$45,350
OzempicSemaglutide33$41,127
FarxigaDapagliflozin Propanediol32$37,252
JanuviaSitagliptin Phosphate28$28,116
WegovySemaglutide17$27,091
MounjaroTirzepatide18$23,693
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,841
MyrbetriqMirabegron22$16,897
BelsomraSuvorexant11$9,668
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,616
TradjentaLinagliptin13$6,707
SymbicortBudesonide/Formoterol Fumarate13$5,255
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$3,711
Atorvastatin Calcium384$3,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$40$82,31085 claims
Novo NordiskOzempic, Wegovy$242$68,21850 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$54$50,12357 claims
PfizerEliquis$83$45,35036 claims
Lilly USA, LLCMounjaro$65$23,69318 claims
GSKTrelegy Ellipta$13$19,84121 claims
Astellas Pharma US IncMyrbetriq$124$16,89722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →